Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia

Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that sustain the disease, and ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Laverdière, Isabelle, Boileau, Meaghan, Neumann, Andrea L., Frison, Héloïse, Mitchell, Amanda, Ng, Stanley W. K., Wang, Jean C. Y., Minden, Mark D., Eppert, Kolja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889502/
https://www.ncbi.nlm.nih.gov/pubmed/29921955
http://dx.doi.org/10.1038/s41408-018-0087-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889502/
https://www.ncbi.nlm.nih.gov/pubmed/29921955
http://dx.doi.org/10.1038/s41408-018-0087-2

Ejemplares similares